论文部分内容阅读
本试验由多中心参加,采用随机、双盲和安慰剂对照的方式。1985年～1987年间连续收治1073例急性心梗患者,平均年龄55.5(30～75)岁,其中91%男性。发病后平均13.8(7～21)天随机分组,A组531例口服维拉帕米360mg/d,B组542例则服安慰剂。平均随访23.5个月。随访期间A组有心绞痛者少于B组(18.8％对24.3％,相对危险度0.8,95％可信区间0.5～0.9,P<0.05),再梗塞者略有减少(7.3％时9.0%,NS),然而总死亡率(5.6％对5.4％)、心脏病死亡率(4.0%对4.1％)和猝死率(2.1％对1.8％)
The trial was multicentre, randomized, double-blind, and placebo-controlled approach. Between 1985 and 1987, 1073 consecutive patients with acute myocardial infarction were treated, with an average age of 55.5 (30-75 years), of whom 91% were male. After the onset of an average of 13.8 (7 ~ 21) days were randomized to 531 patients in group A oral verapamil 360mg / d, B group 542 patients were given placebo. The average follow-up of 23.5 months. Patients in group A had fewer angina pectoris than those in group B (18.8% vs. 24.3%, relative risk 0.8, 95% confidence interval 0.5 to 0.9, P <0.05), and a slight decrease in those with reperfusion (9.0% at 7.3% However, total mortality (5.6% versus 5.4%), heart disease mortality (4.0% vs. 4.1%) and sudden death (2.1% vs. 1.8%)